Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2018-02-06 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于转让北京泛生子基因科技有限公司6.483%股权的补充公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the transfer of a 6.483% equity stake in Beijing Genomics Gene Technology Co., Ltd. It includes information about the transaction parties, reasons for the transfer, accounting treatment, and risk disclosures. The content focuses on a specific equity transfer transaction and related corporate disclosures rather than financial results, management changes, or regulatory certifications. It is not a full financial report, earnings release, or management discussion. The document is a supplemental announcement related to a capital transaction (equity transfer) and does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a capital/financing update about shareholding changes and equity transfer details. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 3292 characters, which is sufficient for a detailed announcement rather than a brief report publication announcement or regulatory filing fallback.
2018-02-06 Chinese
2018年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2018 First Extraordinary General Meeting" of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes the meeting agenda, voting procedures, and a specific proposal to appoint a new supervisor to the board. The content focuses on the meeting logistics, shareholder voting, and board member changes. There are no financial statements, earnings data, or audit information. The document is clearly a presentation or materials shared for a shareholders' meeting, specifically an Extraordinary General Meeting (EGM). This fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings. The document length is short and it is not an announcement of a report but the actual meeting materials. Therefore, the correct classification is AGM Information (AGM-R).
2018-02-06 Chinese
独立董事关于转让北京泛生子基因科技有限公司6.483%股权的独立意见
Regulatory Filings Classification · 90% confidence The document is an independent opinion from the independent directors regarding the transfer of a 6.483% equity stake in Beijing Genomics Co., Ltd. It discusses the legality, benefits, and fairness of the transaction to shareholders and recommends approval at the shareholders' meeting. The document is not a full report but an opinion related to a specific transaction. It does not contain financial statements or detailed financial data. It is not an announcement of voting results but a management/board opinion on a transaction. This fits best under Regulatory Filings (RNS) as it is a regulatory disclosure related to governance and transaction approval but not a full management report or capital update.
2018-02-05 Chinese
关于转让北京泛生子基因科技有限公司6.483%股权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the transfer of a 6.483% equity stake in Beijing Genomics Gene Technology Co., Ltd. by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes transaction details, parties involved, financial data of the target company, shareholder structure, pricing basis, terms of the agreement, conditions precedent, delivery and payment terms, breach and termination clauses, and the impact on the company. The document is not a financial report, audit report, or earnings release. It is not a regulatory filing or a report publication announcement because it contains substantive transaction details and financial data related to the equity transfer. The content fits the category of Capital/Financing Update (CAP) as it concerns a significant equity transfer transaction and related financing matters.
2018-02-05 Chinese
关于延长第一期员工持股计划存续期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of 中源协和细胞基因工程股份有限公司 regarding the extension of the duration of the first employee stock ownership plan. It details the approval process, the number of shares purchased under the plan, and the decision to extend the plan's term. There is no financial report, earnings data, or detailed management discussion. The document is a formal announcement about a capital-related employee share plan extension, which fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2018-02-05 Chinese
第九届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 12th meeting of the 9th Board of Directors of the company. It details voting results on various corporate matters such as equity transfer, capital increase, extension of employee stock plan duration, and convening a shareholders' meeting. The document does not contain financial statements or detailed financial performance data. It is a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or presentation but a formal announcement of board decisions.
2018-02-05 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.